is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY We look forward to presenting our next readout of interim results.”ĪBOUT SERNOVA CORP. Philip Toleikis, President and Chief Executive Officer of Sernova, added, “With the first two patients transplanted and a third patient now implanted with the higher capacity Cell Pouch, we are pleased to see the successful results of our patient enrollment acceleration strategy and are driving to complete full enrollment as expeditiously as possible. “I look forward to reporting the first interim results of the second patient cohort.”ĭr. Piotr Witkowski, Clinical Trial Principal Investigator and Director of the Pancreatic Islet Transplant Program at the University of Chicago. “I am excited to apply the learnings from the first patient cohort, including implementation of the higher capacity Cell Pouch, which enables us to optimize the dose and concentration of islets to achieve our clinical objectives with these patients,” said Dr. The higher capacity 10-channel Cell Pouch provides greater than 50% more capacity relative to the Cell Pouches used for the T1D Study’s first cohort. These endpoints include survival of transplanted islet cells, reduction of severe hypoglycemic episodes, and changes in HbA1c, serum C-peptide production, and insulin requirements. The amended protocol to use the 10-channel Cell Pouch enables optimized dosing and shorter efficacy evaluation periods to ultimately decrease time to key efficacy endpoints. ![]() Enrollment for the new second cohort has occurred rapidly with approximately half of the patients already completed. The amended protocol includes a second cohort of up to seven patients for the transplant of islets into Sernova’s higher-capacity Cell Pouch. In November 2022, the Company announced the addition of a second cohort and protocol amendment for its T1D Study. Additionally, a third enrolled patient has now been implanted with the higher capacity Cell Pouch and awaits islet transplant in the coming weeks. These patients will be monitored for safety and efficacy for three months after which a second dose of islets is anticipated to be transplanted in accordance with the protocol. Phase 1/2 clinical trial for the treatment of type 1 diabetes (“T1D”) and hypoglycemia unawareness (the “T1D Study”) received their first islet transplant into the higher capacity 10-channel Cell Pouch™. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second cohort of its active U.S. LONDON, Ontario, Ma(GLOBE NEWSWIRE) - Sernova Corp. Company anticipates first interim data from second cohort in Q4 2023.Third patient now implanted with higher capacity, 10-chamber Cell Pouch.The first one is free, the second one is commercial, but you can pay the amount you want, minimum $4.11 I do use this program as my personal choice. It comes in two flavours Ommwriter Dana I and Ommwriter Dana II. I used WriteRoom for free a couple of years ago, now the product has evolved and is commercial but surely the most complete of all. ![]() This is the environment where I use this kind of programs the most. Here is the list of distraction-free software for both Windows and Mac. It might sound simple or even ridiculous, but I am more productive when I stop receiving notifications and being tempted of clicking on that little red number showing unread email or any other procastinators. These programs usually are full-screen and only let you see the text you are typing, and usually plain text (without any formats). For anyone who works with a computer and needs to write text in a non-distracting environment these tools will be very useful. ![]() I am not a writer, but as many other mortals a lot of times I need to write long documents or put my ideas alltogether. Best distraction-free writing programs Wed, Oct 20, 2010
0 Comments
Leave a Reply. |